June 2024
1. ELKHOLI IE, Rose AAN, Aguirre-Ghiso JA, Cote JF, et al
   How can we integrate the biology of breast cancer cell dormancy into clinical practice?
   Cancer Cell. 2024 Jun 12:S1535-6108(24)00191-0. doi: 10.1016/j.ccell.2024.
   

   >> Share

   
   
2. LI Y, Huang M, Wang M, Wang Y, et al
   Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite.
   Cancer Cell. 2024;42:985-1002.
   

   >> Share

   
   May 2024
3. MCGINNIS CS, Miao Z, Superville D, Yao W, et al
   The temporal progression of lung immune remodeling during breast cancer metastasis.
   Cancer Cell. 2024 May 24:S1535-6108(24)00167-3. doi: 10.1016/j.ccell.2024.
   

   >> Share

   
   
4. LAYER N, Bunse L, Venkataramani V
   Neural deception: Breast cancer co-opts neuronal mechanisms to evade the immune system.
   Cancer Cell. 2024 May 17:S1535-6108(24)00170-3. doi: 10.1016/j.ccell.2024.
   

   >> Share

   
   April 2024
5. LIN CJ, Jin X, Ma D, Chen C, et al
   Genetic interactions reveal distinct biological and therapeutic implications in breast cancer.
   Cancer Cell. 2024;42:701-719.
   

   >> Share

   
   March 2024
6. BEJARANO L, Kauzlaric A, Lamprou E, Lourenco J, et al
   Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms.
   Cancer Cell. 2024;42:378-395.
   

   >> Share

   
   January 2024
7. SHIAO SL, Gouin KH 3rd, Ing N, Ho A, et al
   Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer.
   Cancer Cell. 2024;42:70-84.
   

   >> Share

   
   
8. GODDARD ET, Linde MH, Srivastava S, Klug G, et al
   Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies.
   Cancer Cell. 2024;42:119-134.
   

   >> Share

   
   
9. SHAITELMAN SF, Woodward WA
   Neoadjuvant radioimmunotherapy synergy in triple-negative breast cancer: Is microenvironment-guided patient selection on the horizon?
   Cancer Cell. 2024;42:10-12.
   

   >> Share

   
   December 2023
10. SREEKUMAR A, Lu M, Choudhury B, Pan TC, et al
    B3GALT6 promotes dormant breast cancer cell survival and recurrence by enabling heparan sulfate-mediated FGF signaling.
    Cancer Cell. 2023 Dec 1:S1535-6108(23)00399-9. doi: 10.1016/j.ccell.2023.
    

    >> Share

    
    May 2023
11. HUTTEN SJ, de Bruijn R, Lutz C, Badoux M, et al
    A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.
    Cancer Cell. 2023;41:986-1002.
    

    >> Share

    
    
12. MAGBANUA MJM, Brown Swigart L, Ahmed Z, Sayaman RW, et al
    Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
    Cancer Cell. 2023 May 3:S1535-6108(23)00134-4. doi: 10.1016/j.ccell.2023.
    

    >> Share

    
    April 2023
13. MOUSSET A, Lecorgne E, Bourget I, Lopez P, et al
    Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-beta activation.
    Cancer Cell. 2023;41:757-775.
    

    >> Share

    
    February 2023
14. VIRASSAMY B, Caramia F, Savas P, Sant S, et al
    Intratumoral CD8(+) T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer.
    Cancer Cell. 2023 Feb 8:S1535-6108(23)00004-1. doi: 10.1016/j.ccell.2023.
    

    >> Share

    
    December 2022
15. BLOMBERG OS, Spagnuolo L, Garner H, Voorwerk L, et al
    IL-5-producing CD4(+) T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.
    Cancer Cell. 2022 Dec 14:S1535-6108(22)00561-X. doi: 10.1016/j.ccell.2022.
    

    >> Share

    
    
16. BEHBOD F, Khan SA
    Towards the development of DCIS risk prediction models.
    Cancer Cell. 2022;40:1461-1464.
    

    >> Share

    
    
17. STRAND SH, Rivero-Gutierrez B, Houlahan KE, Seoane JA, et al
    Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.
    Cancer Cell. 2022;40:1521-1536.
    

    >> Share

    
    
18. GRISARU-TAL S, Munitz A
    T cell-eosinophil crosstalk-A new road for effective immune checkpoint blockade in breast cancer?
    Cancer Cell. 2022 Dec 10:S1535-6108(22)00555-4. doi: 10.1016/j.ccell.2022.
    

    >> Share

    
    November 2022
19. LIU X, Lu Y, Huang J, Xing Y, et al
    CD16(+) fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition.
    Cancer Cell. 2022;40:1341-1357.
    

    >> Share

    
    June 2022
20. DENKERT C, Loibl S
    Response-based molecular subtyping-emergence of the third generation of breast cancer subtypes.
    Cancer Cell. 2022;40:592-594.
    

    >> Share

    
    May 2022
21. WOLF DM, Yau C, Wulfkuhle J, Brown-Swigart L, et al
    Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
    Cancer Cell. 2022 May 25. pii: S1535-6108(22)00216.
    

    >> Share

    
    November 2021
22. KOH SB, Ellisen LW
    Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer.
    Cancer Cell. 2021 Nov 8. pii: S1535-6108(21)00601.
    

    >> Share

    
    October 2021
23. ZHANG Y, Chen H, Mo H, Hu X, et al
    Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer.
    Cancer Cell. 2021 Oct 5. pii: S1535-6108(21)00499.
    

    >> Share

    
    September 2021
24. SHIAO SL, Kershaw KM, Limon JJ, You S, et al
    Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy.
    Cancer Cell. 2021;39:1202-1213.
    

    >> Share

    
    August 2021
25. HANKER AB, Brown BP, Meiler J, Marin A, et al
    Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.
    Cancer Cell. 2021;39:1099-1114.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share